← Leaderboards
James K Richardson
University Of Michigan At Ann Arbor
$3,588,324
Attributed
$3,716,614
Total exposure
18
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $304.7K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,716,614 · 18
By mechanism
R01$1,487,970 · 1
P60$731,331 · 1
K23$710,770 · 1
M01$529,963 · 14
R41$256,580 · 1
Top collaborators
- Nicolaas Bohnen1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Robert D Gregg$7,895,936
- Chandramouli Krishnan$1,906,005
- James Anthony Ashton-Miller$9,179,244
- Maryfran R Sowers$31,711,856
- Cara L Lewis$1,745,540
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationAids TherapyHiv InfectionsCombination ChemotherapyProtease InhibitorDrug Screening /EvaluationReverse Transcriptase InhibitorsAntiaids AgentIndinavirGaitLamivudineZidovudineExerciseAnkleHuman Old Age (65+)Clinical TrialsHuman Immunodeficiency VirusAssistive Device /TechnologySensorimotor SystemBalanceDosageStavudine
Grant awards (73)
Development of a Multifunctional Rehabilitation Standing and Stepping Device for Persons with Parkinson's Disease$256,580
R41 · FY2022 · NS
Neuropathic Gait, Irregular Surfaces and Fall Risk$288,789
R01 · FY2012 · AG · contact PI
Neuropathic Gait, Irregular Surfaces and Fall Risk$289,086
R01 · FY2011 · AG · contact PI
Neuropathic Gait, Irregular Surfaces and Fall Risk$301,053
R01 · FY2010 · AG · contact PI
Neuropathic Gait, Irregular Surfaces and Fall Risk$304,382
R01 · FY2009 · AG · contact PI
Neuropathic Gait, Irregular Surfaces and Fall Risk$304,660
R01 · FY2008 · AG · contact PI
THREE PROTEASE INHIBITOR-SPARING REGIMENS FOR INITIAL RX OF HIV (A5095)$40,935
M01 · FY2006 · RR · contact PI
LOPINAVIR/RITONAVIR VS GW433908 & RITONAVIR/LOPINAVIR AND GW433908$730
M01 · FY2006 · RR · contact PI
THREE PROTEASE INHIBITOR-SPARING REGIMENS FOR INITIAL RX OF HIV (A5095)$220,841
M01 · FY2005 · RR
LOPINAVIR/RITONAVIR VS GW433908 &RITONAVIR/LOPINAVIR AND GW433908$2,383
M01 · FY2005 · RR
Three Protease Inhibitor-Sparing Regimens for Initial Rx of HIV (A5095)$246,418
M01 · FY2004 · RR
PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS &BALANCE$144,896
K23 · FY2004 · AG
Lopinavir/Ritonavir vs GW433908 &Ritonavir/Lopinavir and GW433908$11,660
M01 · FY2004 · RR
Study of Development of Distal Symmetrical Polyneuropathy in HIV-1 pts$4,664
M01 · FY2004 · RR
Pharmacokinetic-Adjusted Phenotype Susceptibility (C12h/IC50)- A5126,Ver 1.0$1,555
M01 · FY2004 · RR
Studies of Amprenavir,Efavirenz &Protease Inhibitor in HIV seroneg.pts (A5043)$777
M01 · FY2004 · RR
PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS &BALANCE$140,675
K23 · FY2003 · AG
Peripheral neuropathy, sensorimotor function and balance$196,218
P60 · FY2002 · AG
PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS &BALANCE$136,579
K23 · FY2002 · AG
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2002 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2002 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2002 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2002 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2002 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2002 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2002 · RR
Peripheral neuropathy, sensorimotor function and balance$196,218
P60 · FY2001 · AG
PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS &BALANCE$137,556
K23 · FY2001 · AG
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2001 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2001 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2001 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2001 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2001 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2001 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2001 · RR
Peripheral neuropathy, sensorimotor function and balance$196,218
P60 · FY2000 · AG
PERIPHERAL NEUROPATHY, SENSORIMOTOR FUNCTIONS &BALANCE$151,064
K23 · FY2000 · AG
Peripheral neuropathy, sensorimotor function and balance$142,677
P60 · FY2000 · AG
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2000 · RR
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2000 · RR
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2000 · RR
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2000 · RR
PROTEASE INHIBITORS &LIPID LOWERING AGENTS INTERACTIONS$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION BY TRIPLE COMBINATION REGIM W/ DIDA$0
M01 · FY2000 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR
IPHARMACOKINETIC NTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR/NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ, NELFINAVIR, LAMIVUDINE &ZIDOVUDINE, INDINAVIR IN HIV$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP266 AND 1592U89$0
M01 · FY2000 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2000 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2000 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2000 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2000 · RR
PROSPECTIVE RANDOMIZED DOUBLE BLIND TRIAL OF MAINTENANCE REGIMENS FOR HIV$0
M01 · FY2000 · RR